Gunning for new targets, new approaches

From CAR-T cells to protein degradation

September 19, 2023

Targeted Therapy Trials: Why some drug developers keep missing the mark

Do we need to pay more attention to the underlying biology in aggressive lymphomas?

September 5, 2023

Standing out from the crowd in AML

Encouraging new developments in the CAR-NK niche

June 27, 2023

Next generation CAR-T cell therapies for the future

From autologous to gene edited CARs and much in between - W2W4 on 14 next gen products

June 22, 2023

Seeing the wood from the trees in early stage oncology pipelines

Exploring future IO-IO combination strategies and life cycle management

June 16, 2022

The Forgotten Checkpoints

What can we learn from the data on inhibitory checkpoints not named PD(L)1 or TIGIT?

May 26, 2022

Making a difference in aggressive lymphomas

Round-up of key highlights relating to CAR-T cell therapies, CELMoDs and super-enhancer activity in DLBCL

June 22, 2021

New developments in hematologic malignancies to make your head turn

A look at two under the radar early developments in lymphomas which might have a shot at approval

June 17, 2021

A look at 6 key developments in advanced hematologic malignancies

A look at 6 IO products in the Heme space and what to watch out for.

June 10, 2021

Pillars of future strategies in tackling aggressive lymphomas

Some intriguing new developments in DLBCL to watch out for

August 20, 2020